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Summary
Background In myelodysplastic syndromes, thrombocytopenia is associated with mortality, but treatments in this 
setting are scarce. We tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in improving 
thrombocytopenia in lower-risk myelodysplastic syndromes and severe thrombocytopenia.
Methods EQoL-MDS was a single-blind, randomised, controlled, phase 2 superiority trial of adult patients with low-risk 
or International Prognostic Scoring System intermediate-1-risk myelodysplastic syndromes and severe thrombo-
cytopenia. Patients with a stable platelet count of lower than 30 × 10⁹ platelets per L, aged at least 18 years, with 
refractoriness, ineligibility to receive treatment with alternative medications, or relapse while receiving treatment with 
alternative medications were included in this trial. Patients were randomly assigned (2:1) to receive eltrombopag (50 mg 
to 300 mg) or placebo for at least 24 weeks and until disease progression and were masked to treatment allocation. Here, 
we report the results in the intention-to-treat population of the first phase of the trial, for which the primary endpoints 
were the proportion of patients achieving a platelet response within 24 weeks and safety. The interim analysis presented 
here was protocol-specified and used a two-sided significance level of 0·001 and a p value at or below this limit for both 
primary endpoints to indicate the need for early trial termination. Duration of platelet transfusion independence, 
duration of response, overall survival, leukaemia-free survival, and pharmacokinetics will be reported at the end of the 
phase 2 portion of the trial. This trial is registered with EudraCT, number 2010-022890-33.
Findings Between June 13, 2011, and June 17, 2016, we enrolled 90 participants for the first phase of the trial. The 
median follow-up time to assess platelet responses was 11 weeks (IQR 4–24). Platelet responses occurred in 28 (47%) 
of 59 patients in the eltrombopag group versus one (3%) of 31 patients in the placebo group (odds ratio 27·1 [95% CI 
3·5–211·9], p=0·0017). During the follow-up, 21 patients had at least one severe bleeding event (WHO bleeding 
score ≥2). There were a higher number of bleeders in the placebo (13 [42%] of 31 patients) than in the eltrombopag 
arm (eight [14%] of 59 patients; p=0·0025). 52 grade 3–4 adverse events occurred in 27 (46%) of 59 patients in the 
eltrombopag group versus nine events in five (16%) of 31 patients in the placebo group (χ²=7·8, p=0·0053, stopping 
rule not reached). The outcome acute myeloid leukaemia evolution or disease progression occurred in seven (12%) of 
59 patients in the eltrombopag group versus five (16%) of 31 patients in the placebo group (χ²=0·06, p=0·81).
Interpretation Eltrombopag is well-tolerated in patients with lower-risk myelodysplastic syndromes and severe 
thrombocytopenia and is clinically effective in raising platelet counts and reducing bleeding events. The assessment 
of long-term safety and efficacy of eltrombopag and its effect on survival (phase 2 part of study) is still ongoing.
Funding Associazione QOL-ONE.
Introduction
Myelodysplastic syndromes are clonal myeloid neo plasms 
characterised by ineffective haemopoiesis, dysplastic 
haemopoiesis, cytopenias, and a substantial risk of 
progression to acute myeloid leukaemia.1 Anaemia is 
prevalent in individuals with myelodysplastic syndromes, 
but about 10% of individuals with low-risk myelodysplastic 
syndromes (low-risk and intermediate-1-risk, according to 
the International Prognostic Scoring System [IPSS]) have 
thrombocytopenia with platelet counts lower than 
30 × 10⁹ platelets per L.2,3 In such patients, both low platelet 
counts and platelet function abnormalities contribute to 
the risk of bleeding.3 New prognostic scoring systems, 
such as the revised IPSS, take into account the effect of 
thrombo cytopenia severity on survival.4–6
Patients with low-risk myelodysplastic syndromes and 
thrombocytopenia receive platelet transfusions, mainly in 
the presence of either bleeding or severe thrombocytopenia 
(<10 × 10⁹ platelets per L).7 Short therapeutic effect and 
refractoriness to platelet transfusions provide an impetus 
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to research novel treatments.8,9 Azacitidine is approved by 
the United States Food and Drug Administration for the 
treatment of patients with myelodysplastic syndromes, 
including low-risk patients with thrombocytopenia,10 
whereas the European Medicines Agency limits treatment 
with azacitidine to IPSS intermediate-2 and high-risk 
patients.11 Therefore, the treatment of thrombocytopenia 
in low-risk patients remains a medical need that is unmet 
in most parts of the world.12
Thrombopoietin is the principal cytokine involved in the 
regulation of platelets by binding to its specific cellular 
receptor TPO-R.13 Eltrombopag is an orally bioavailable, 
small molecule TPO-R agonist that is approved in Europe 
and the USA for the treatment of a subset of patients with 
immune thrombocytopenic purpura or idiopathic thrombo-
cytopenic purpura in adult patients with chronic hepatitis 
C virus infection to facilitate interferon-based therapy, and 
adult patients with acquired severe aplastic anaemia who 
show an insufficient response to immuno suppressive 
therapy.14,15 We designed this phase 2 clinical trial to assess 
eltrombopag in adult patients with low-risk or IPSS 
intermediate-1-risk myelodysplastic syndromes and severe, 
persistent thrombocytopenia (<30 × 10⁹ platelets per L).
Methods
Study design and participants
EQoL-MDS was a randomised, single-blind, placebo-
controlled, phase 2 superiority trial in patients with 
myelodysplastic syndromes from hospitals in Italy, 
France, Germany, and Slovenia. The trial was divided 
into two phases: the first (phase 1) was to determine the 
efficacy and safety of eltrombopag and the second was to 
assess the long-term response and safety (phase 2; 
appendix p 2). This trial reports phase 1 outcomes.
Patients had centrally and blinded confirmed morpho-
logical diagnosis of low-risk or IPSS intermediate-1 risk 
myelodysplastic syndromes with a stable platelet count of 
lower than 30 × 10⁹ platelets per L. Cases with more than 
5% blasts were not included in France. Patients aged at 
least 18 years, with refractoriness, ineligibility to receive 
treatment with alternative medications, or relapse while 
receiving treatment with alternative medications were 
included in this trial. Erythropoiesis-stimulating drugs or 
granulocyte colony-stimulating factor were permitted 
during the trial, as per accepted standards. Patients were 
excluded from the study if they had received previous 
chemoradiotherapy or TPO-R agonists; peripheral 
monocytosis of more than 1 × 10⁹ cells per L or leukocytosis 
of at least 25 × 10⁹ cells per L; marrow fibrosis with an 
inability to aspirate marrow; an Eastern Cooperative 
Oncology Group performance status16 higher than 3; a 
creatinine concentration more than two times the upper 
limit of normal (110 μmol/L), a serum aspartate 
aminotransferase or alanine aminotransferase more than 
three times the upper limit of normal (6–34 IU/L in men; 
8–40 IU/L in women), or a serum bilirubin more than 
Research in context
Evidence before this study
In 2009, we did a literature search using the PubMed database to 
identify published studies of the effect and treatment of 
thrombocytopenia in myelodysplastic syndromes, with no date 
restrictions. We used the search terms “thrombocytopenia” and 
“myelodysplastic syndromes”. The search returned a number of 
reviews describing the negative effect of thrombocytopenia on 
patients with myelodysplastic syndromes. In low-risk and 
International Prognostic Scoring System (IPSS) 
intermediate-1-risk myelodysplastic syndromes with severe 
thrombocytopenia, the only globally accepted treatment was 
platelet transfusions; the hypomethylating and 
disease-modifying drug azacitidine was approved by the US Food 
and Drug Administration, but not specifically for the treatment of 
thrombocytopenia. No report had yet been published of a 
randomised clinical trial assessing a thrombopoietin-receptor 
agonist in this indication. Phase 1/2 trials with romiplostim had 
yielded some positive safety and efficacy data, but no assessment 
of eltrombopag in myelodysplastic syndromes had yet been 
published or registered on the ClinicalTrials.gov website.
Added value of this study
To our knowledge, this is the first randomised, 
placebo-controlled clinical trial to assess eltrombopag in the 
treatment of patients with low-risk and IPSS intermediate-1-risk 
myelodysplastic syndromes and thrombocytopenia. The results 
obtained showed that treatment with eltrombopag induces 
platelet responses and improvements in patient-reported 
outcomes (quality of life). Progression of myelodysplastic 
syndromes and acute myeloid leukaemia evolution did not differ 
in patients receiving eltrombopag versus those allocated to 
placebo. Treatment-related adverse events, particularly nausea 
and vomiting, were problematic in a few patients, and led to 
five premature discontinuations in the eltrombopag group; 
however, the treatment was well tolerated overall. Our findings 
confirm eltrombopag as an important new therapeutic option 
for thrombocytopenia in patients with low-risk and IPSS 
intermediate-1-risk myelodysplastic syndromes, and the first oral 
drug to be proven beneficial in this setting.
Implications of all the available evidence
The development of treatments for cytopenias associated with 
myelodysplastic syndromes is a key therapeutic aim. Recent trials 
of eltrombopag in intermediate-2-risk and high-risk 
myelodysplastic syndromes showed no evidence of clinical 
benefits; however, the positive results that we report show the 
potential of eltrombopag in lower-risk myelodysplastic syndromes. 
Our findings might provide valuable evidence to support the 
approval of this new therapeutic option for the subset of patients 
with myelodysplastic syndromes and severe thrombocytopenia.
See Online for appendix
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1·5 times the upper limit of normal (0–7 µmol/L); and 
pre-existing cardiovascular disease or arrhythmia 
associated with an increased thromboembolic event risk.
All trial personnel received good clinical practice 
training and certification, and all procedures were done 
in accordance with the tenets of the Declaration of 
Helsinki. The protocol conformed to the ethical guidelines 
of all institutions and received approval by Ethical 
Committees of participating centres and country 
regulatory authorities. Written informed consent was 
obtained by each participant at inclusion.
Randomisation and masking
Patients were centrally randomised (2:1 ratio) to receive 
either eltrombopag or placebo treatment for at least 
24 weeks, and until progression. Randomisation was 
done by the statistician (Dielnet Srl, Reggio Calabria, 
Italy) using the simple randomisation method with the 
sequence being generated by means of the RAND 
function of the Excel software programme. The 
sequence was uploaded to a protected database, Secure 
Sockets Layer certificated on a server’s web interface, 
guaranteeing allocation concealment. After the 
compilation of a specific electronic case report form, 
each enrolled patient was centrally assigned to the first 
available position on the randomisation list. The 
investigator was able to see, directly from the completed 
case report form, which group the patient was assigned 
to. The allocation sequence was transferred to Depo 
Pack snc, Saronno, Italy, where independent labels 
were applied with sequential code numbers on the 
appropriate bottles. Patients were masked to the 
allocation (single-blinded design). Trial medication was 
dispensed to patients by the supervising clinician at 
each of the participating centres. Tablets were packaged 
by Depo Pack snc in white, opaque, high-density 
polyethylene bottles containing 35 tablets each. Each 
bottle had child-resistant closures and was affixed with 
a blinded label with the study protocol number, patient 
randomisation number, and all additional required 
information. The contents of the label were in 
accordance with all applicable regulatory requirements.
Procedures
After baseline peripheral and bone marrow morphological 
assessment, accompanied by local cytogenetic analysis, 
subsequent assessments were done at 3 months and 
6 months. Hepatitis B virus and hepatitis C virus testing 
and coagulation assays were done before randomisation. 
Complete blood count, liver, and renal chemistry were 
assessed at baseline, weekly for the first 4 weeks, every 
2 weeks for the following 8 weeks, and monthly thereafter. 
Patients included in this analysis received oral 
eltrombopag or matching placebo at an initial dose of 
50 mg once daily, titrated in 50 mg increments every 
2 weeks up to a maximum of 300 mg to achieve the target 
platelet level of 100 × 10⁹ platelets per L. Dose reductions 
were required for platelet concentrations greater than 
200 × 10⁹ platelets per L or adverse events, according to 
protocol specifications.
Platelet response, defined according to International 
Working Group criteria,17 was assessed at each visit. 
Titration for maintenance to intermediate doses was 
done to maintain platelet counts between at least 100 × 10⁹ 
platelets per L and 200 × 10⁹ platelets per L or less. 
Patients whose platelet count exceeded 200 × 10⁹ platelets 
per L at any point during the treatment period had study 
drug decreased by 25 mg.
Temporary interruptions and titrations of trial 
medication were predetermined for platelet counts of 
more than 300 × 10⁹ platelets per L, grade 3 to 4 toxicities 
(according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events version 4.0), and 
blast increases that met the definition of progression of 
myelodysplastic syndromes.17 At resolution, treatment 
was restarted at the next lower dose level. Response was 
considered long-lasting if maintained for more than 
4 weeks.
Trial medication was withdrawn if patients had no 
response after 4 weeks at maximum tolerated dose, 
persistent grade 3 to 4 drug-related adverse events, 
irreversible progression of myelodysplastic syndromes, 
were pregnant, withdrew consent, did not comply with 
the protocol, or had a major protocol violation. 
A randomly assigned patient was considered to have 
completed the study if they died, withdrew consent, or 
were lost to follow-up.
Outcomes
The primary outcomes for phase 1 of this trial were the 
proportion of patients achieving a complete or partial 
response, and safety and tolerability parameters, 
including grade 3 to 4 non-haematological laboratory 
toxicities, changes in bone marrow blast counts from 
baseline, and adverse events. Complete platelet response 
was defined as a platelet count of at least 100 × 10⁹ platelets 
per L without bleeding, with the following increases in 
platelet count from baseline levels: for patients with 
baseline platelets at least 20 × 10⁹ platelets per L, an 
increase of at least 30 × 10⁹ platelets per L from baseline; 
and for patients with baseline platelets less than 
20 × 10⁹ platelets per L, an increase of more than 
20 × 10⁹ platelets per L and an increase of at least 100%, 
not due to platelet transfusions. Partial platelet response 
was defined as absence of bleeding, and either an absolute 
increase in platelet count to at least 30 Gi/L for patients 
starting with more than 20 × 10⁹ platelets per L or an 
increase from less than 20 × 10⁹ platelets per L to at least 
20 × 10⁹ platelets per L and by at least 100%, not due to 
platelet transfusion.
Secondary endpoints included time to response, 
frequency of platelet transfusions, incidence and severity of 
bleeding, changes in quality-of-life score, measured at 
baseline and every 3 months by the EORTC QLQ-C30 
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questionnaire,18 and the myelodysplastic syndromes-
specific QOL-E questionnaire.19 Phase 2 of the trial will 
comprise assessment of duration of platelet response and 
long-term safety and tolerability. The interim analysis 
presented in this study only focuses on phase 1 of the study.
Statistical analysis
The target sample size was calculated assuming that 15% 
and 55% of placebo and eltrombopag recipients, 
respectively, would achieve a platelet response. We further 
postulated that 10% of patients in the eltrombopag group 
versus 2% of patients in the placebo group would 
experience grade 3 to 4 hepatotoxicity; and that 10% of 
platelet responders and 80% of non-responders would 
experience grade 3 or worse adverse events not related to 
the trial medication. Given these assumptions, we 
expected 50% of patients in the eltrombopag group versus 
72% of patients in the placebo group to experience at least 
one grade 3 or worse toxic event. With the use of a two-
sided χ² test with α=0·05 for both endpoints, 63 patients 
would be required to detect a difference in platelet 
response rate (90% power), and 174 patients would be 
required to detect a difference in the proportion of 
patients with grade 3 or worse adverse events (80% power). 
Therefore, 174 patients (116 in the eltrombopag group and 
58 assigned to placebo) needed to be enrolled to meet the 
requirements for both primary endpoints.
The final analysis will be done at the 0·05 significance 
level (two-sided test) according to the Haybittle-Peto 
method.20 Efficacy and safety data analyses were done in 
the intention-to-treat population. Any patient who 
received a randomisation number was considered to 
have been randomly assigned and was included in the 
efficacy and safety analyses. Missing data were not 
imputed.
Time to response was calculated as the time from 
randomisation to the date of achievement of a complete or 
partial response and was compared between treatment 
groups by Kaplan-Meier analysis. Significant predictors of 
response were identified by logistic regression analysis, 
and data were expressed as odds ratios (ORs), 95% CIs, 
and p values. Between-treatment comparisons of safety 
data (adverse events, progression of myelodysplastic 
syndromes progression and evolution of acute myeloid 
leukaemia, and death) were done using a χ² test. The 
number needed to treat (for platelet response) and number 
needed to harm (for treatment-emergent adverse events) 
were also calculated as measures of the clinical impact of 
eltrombopag. The number needed to treat and number 
needed to harm were combined by calculating the 
likelihood of being helped or harmed21 (a ratio of the 
two numbers that indicated how many times eltrombopag 
was more likely to help than to harm). This index was only 
calculated for harmful effects which were more frequent 
in the eltrombopag group than in the placebo group.
The effect of eltrombopag on platelet response over 
time and the effect of eltrombopag and platelet changes 
over time on each scale of each quality-of-life 
questionnaire were further investigated by linear mixed 
models.22 In these models, data were expressed as 
regression coefficients, 95% CIs, and p values. The effect 
of a range of variables on platelet response to eltrombopag 
was investigated by introducing into the same models 
the treatment (0=placebo, 1=eltrombopag), potential 
effect modifier, and interaction term “treatment × effect 
modifier”. The difference (eltrombopag – control) and 
95% CI in platelet count throughout the trial period, 
according to predefined effect modifier categories, was 
then calculated by a linear combination method. 
Data analysis was done with SPSS for Windows, 
version 19, and Stata for Windows, version 13.1. An 
independent data and safety monitoring board oversaw 
the trial, confirmed data integrity, and approved the 
results and report for release. This trial was registered 
with EudraCT, number 2010-022890-33.
Role of the funding source
The funder of the study contributed to study design, data 
collection, data analysis, data interpretation, writing of 
153 patients were assessed for eligibility
90 underwent randomisation (2:1)
59 were assigned to eltrombopag 31 were assigned to placebo
59 included in intention-to-treat phase 1 analysis
52 were still under observation at interim analysis
 34 were receiving eltrombopag
 18 were receiving placebo
31 included in intention-to-treat phase 1 analysis
25 discontinued prematurely
 8 withdrew the consent
 5 had persistent adverse events
 4 had acute myeloid leukaemia evolution
 2 had myelodysplastic syndrome 
  progression
 2 had liver toxicity
 2 had solid tumour
 1 died
 1 violated the protocol
63 were excluded
 25 had unconfirmed diagnosis
 17 had platelet count higher >30 Gi/L
 7 had invaluable bone marrow
 3 had elevated liver enzymes
 3 withdrew consent
 2 died before screening
 6 excluded for other reasons
13 discontinued prematurely
 11 withdrew the consent
 1 was lost to follow-up
 1 had myelodysplastic syndrome 
  progression
Figure 1: Trial profile
*25 patients in the eltrombopag group and 13 patients in the placebo group discontinued prematurely and were 
hence censored.
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the report, and the decision to submit the report for 
publication. The funder also paid for the services of 
professional medical writers, who provided editorial 
assistance in refining the draft manuscript, and a 
statistician, who carried out the statistical data analyses. 
All authors had full access to all the trial data in the study 
and were responsible for the decision to submit for 
publication.
Results
Between June 13, 2011, and June 17, 2016, we enrolled 
90 participants for the first phase of the trial, which 
coincided with the interim analysis of 50% of the total 
planned cohort. 153 patients were screened and 90 
randomly assigned (figure 1). The treatment groups were 
similar with respect to baseline characteristics, except for 
a marginally higher prevalence of hypoplastic bone 
marrow in the eltrombopag group than in the placebo 
group (table 1). 90% of all patients were on corticosteroids, 
2% were on deferasirox, and 12% were on erythropoiesis-
stimulating drugs, with similar percentages in the 
individual treatment groups.
 The median follow-up time to assess platelet responses 
was 11 weeks (IQR 4–24); median follow-up time was 
7 weeks (IQR 2–21) in the eltrombopag group and 17 weeks 
(7–24) in the placebo group. Platelet responses were 
observed in 28 (47%) of the 59 eltrombopag recipients 
(11 partial responses and 17 complete responses) versus 
one (3%) partial response of the 31 placebo recipients 
(p<0·0001), giving an OR of 27·1 (95% CI 3·5–211·9, 
p=0·0017). A one-to-one exploratory comparison of 
eltrombopag-treated responders versus non-responders 
is given in the appendix (pp 4–7). In platelet transfusion-
dependent patients in the eltrombopag group, seven (54%) 
of 13 had transfusion independence, five (71%) of whom 
had a platelet response; no patients in the placebo group 
had transfusion independence. 28 patients in the 
eltrombopag group were assessable for cytogenetic 
response at 24 weeks. One responder with del(20q) at 
baseline had a cytogenetic response (normal karyotype). 
By contrast, three cytogenetic progressions were observed 
in the placebo group.
In the eltrombopag group, 23 patients were anaemic, 
of whom 13 experienced haematological erythroid 
improvement. Four platelet responders and two platelet 
non-responders had a durable and significant haemo-
globin rise, as defined by International Working Group 
2006 criteria. Furthermore, nine red blood cell transfusion-
dependent patients became transfusion-independent, so 
that the total number of cases with erythroid improvement 
was 13 (57%) of 23. Of the patients that became 
transfusion-independent, two also had a significant 
haemoglobin response, whereas only three had a 
concomitant platelet response. 16 patients had neutro-
penia. A durable neutrophil response was observed in one 
platelet responder and four platelet non-responders. Of 
note, one of the platelet non-responders had a bilineage 
(erythroid and neutrophil) response. Complete responses 
in terms of platelet response were observed in 17 (29%) of 
59 patients, all in the eltrombopag group.




Age (years) 69 (12) 70 (11) 67 (15)
Sex
Male 52 (58%) 37 (63%) 15 (48%)
Female 38 (42%) 22 (37%) 16 (52%)
Duration of myelodysplastic syndromes (months) 17 (5–50) 21 (7–54) 14 (4–40)
Myelodysplastic syndromes WHO classification at baseline
Refractory anaemia 6 (7%) 2 (3%) 4 (13%)
Refractory thrombocytopenia 25 (28%) 18 (31%) 7 (23%)
Refractory cytopenia with multilineage dysplasia 40 (44%) 25 (42%) 15 (49%)
Refractory cytopenia with multilineage dysplasia and 
ringed sideroblasts
2 (2%) 0 2 (6%)
Refractory anaemia with excess blasts type 1 14 (16%) 12 (20%) 2 (6%)
Myelodysplastic syndrome unclassified 3 (3%) 2 (3%) 1 (3%)
International Prognostic Scoring System risk
Low risk 30 (33%) 17 (29%) 13 (42%)
Intermediate-1 risk 60 (67%) 42 (71%) 18 (58%)
Revised International Prognostic Scoring System
Very low risk 4 (4%) 1 (2%) 3 (10%)
Low risk 55 (61%) 34 (58%) 21 (68%)
Intermediate risk 24 (27%) 18 (31%) 6 (19%)
High risk 7 (8%) 6 (10%) 1 (3%)
Cytogenetics
Normal 63 (70%) 45 (76%) 18 (58%)
Del(5q) 2 (2%) 1 (2%) 1 (3%)
Y chromosome missing 4 (4%) 1 (2%) 3 (10%)
Del(20q) 12 (13%) 7 (12%) 5 (16%)
Del(11q) 1 (1%) 1 (2%) ···
Trisomy 8 4 (4%) 2 (3%) 2 (6%)
Trisomy 15 1 (1%) ··· 1 (3%)
Trisomy 14 1 (1%) 1 (2%) ···
Del(1q) 1 (1%) 1 (2%) ···
Del(9q) 1 (1%) ··· 1 (3%)
WHO score ≥2 9 (10%) 6 (10%) 3 (10%)
Platelet transfusion
Dependent 21 (23%) 13 (22%) 8 (26%)
Independent 69 (77%) 46 (78%) 23 (74%)
Hypoplasia 26 (29%) 21 (36%) 5 (16%)
Fibrosis grade
0 42 (75%) 30 (79%) 12 (67%)
1 12 (21%) 6 (16%) 6 (33%)
2 2 (4%) 2 (5%) 0
Red blood cell transfusion
Dependent 25 (28%) 17 (29%) 8 (26%)
Independent 65 (72%) 42 (71%) 23 (74%)
Haemoglobin (g/dL) 10·9 (2%) 10·8 (3%) 11·3 (2%)






Data are mean (SD), n (%), or median (IQR).
Table 1: Baseline characteristics
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The median daily dose at response was 50 mg (IQR 
50–175). The eltrombopag daily dose at response was 
25 mg in one patient, 50 mg in 17 patients, 100 mg in 
three patients, 150 mg in one patient, 200 mg in 
three patients, 250 mg in two patients, and 300 mg in 
one patient (median daily dose at response was 50 mg). 
Median time to response was 2 weeks (range 1–15) in the 
eltrombopag group (figure 2) and 6 weeks in the one 
responder who received placebo (figure 2). All responsive 
patients required dose titration increases or decreases 
during the first 6 months. Platelet count change at best 
response within the first 6 months was 71 Gi/L in the 
placebo group; median change in the eltrombopag group 
was 124 × 10⁹ platelets per L (IQR 50–217 × 10⁹ platelets 
per L). Median platelet counts at each visit within the first 
6 months are shown in figure 3.
During the 24 week follow-up, among the 21 patients 
who had at least one bleeding event with a WHO bleeding 
score of at least 2, there were a higher number of bleeders 
in the placebo group (13 [42%] of 31 patients) for a total of 
57 events compared with the eltrombopag group (8 [14%] 
of 59 patients) for a total of 42 events (treatment vs control 
group, p=0·0025). 
In the whole group of patients (n=90), with the exception 
of haemoglobin concentration (1 g/dL; OR 1·38; 95% CI 
1·12–1·70, p=0·0024) and, consequently, red blood cell 
transfusion dependence, none of the baseline 
characteristics listed in table 1 or any of the concomitant 
treatments were associated with platelet response 
(appendix). This was also confirmed when the analysis 
was restricted to the eltrombopag treatment group. In a 
linear mixed models analysis (n=836 observations), 
haemoglobin concentration was also found to modify the 
platelet response to eltrombopag, with the between-
treatment difference in platelet count over the trial period 
being closely related to haemoglobin concentrations over 
time (figure 3, appendix p 3). The effect modification by 
haemoglobin on platelet response in the eltrombopag 
group link also exists (p<0·001) by considering 
haemoglobin as a continuous variable. The cutoff values 
in the figure were chosen on pragmatic grounds—ie, by 
moving from severe anaemia (<8 g/dL), to moderate 
anaemia (from 8·1–10 g/dL to 10·1–12·0 g/dL) up to 
acceptable haemoglobin concentrations (>12 g/dL). The 
effect of eltrombopag became apparent at a haemoglobin 
concentration of 8·1 g/dL and increased linearly.
No treatment-related deaths were reported. Incidences 
of grade 3 to 4 non-haematological adverse events were: 
52 in 27 (46%) of 59 eltrombopag recipients versus nine 
in five (16%) of 31 placebo recipients table 2). This 
difference was statistically significant (χ²=7·8, p=0·0053; 
stopping rule not reached). Eight patients required 
permanent treatment discontinuation due to persistent 
drug-related toxicity in the eltrombopag group. Overall, 
no significant between-treatment difference was observed 
in the incidence of grade 1–2 non-haematological adverse 
events (χ²=0·30, p=0·87, appendix pp 8–10). Grade 1 and 
2 adverse events occurring in more than 10% of patients 
did not differ between the treatments groups (χ²=1·85, 
p=0·17; table 2). Four patients in the eltrombopag-treated 
group had leucocytosis associated with myelodysplastic 
syndromes progression or acute myeloid leukaemia. No 
transient increases in circulating peripheral myeloblasts 
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Figure 2: Incidence of platelet response in both treatment groups

































Figure 3: Box and whisker plot of platelet count over time (A) and haemoglobin as an effect modifier of 
platelet response to eltrombopag (B)
In (A), the horizontal line in the middle of each box represents the median, while the top and bottom of each box 
mark the 75th and 25th percentiles, respectively. The whiskers above and below the box plot mark the 97·5th and 
2·5th percentiles, respectively. In B, the horizontal axis shows platelet count difference (eltrombopag vs placebo; 
× 10⁹ platelets per L × 10³) with 95% CIs across the study period.
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group had karyotype evolution without bone marrow 
blast increase compared with one platelet-responsive 
patient in the eltrombopag arm with cytogenetic 
remission.
Acute myeloid leukaemia evolved in four (7%) of the 
59 eltrombopag patients (in weeks 21, 30, 114, and 183, 
respectively) versus one (3%) of the 31 placebo patients 
(week 58; χ²=0·05, p=0·83). The same analysis done by 
the Kaplan-Meier method (ie, by a time-to-event analysis) 
provided similar results (active vs control, p=0·54). The 
three early acute myeloid leukaemia evolutions in the 
eltrombopag group were observed in patients with 
refractory anaemia with excess blasts-1, whereas the 
fourth case occurred in a patient with refractory cytopenia 
with multilineage dysplasia and a 3·4-year history 
of myelodysplastic syndromes. Three (5%) of the 
59 eltrombopag recipients (weeks 37, 62, and 374) versus 
four (13%) of the 31 placebo recipients (three cases at 
week 12 and 1 case at week 33) had disease progression 
(χ²=0·81, p=0·37). Among the patients who had disease 
progression, three had cytogenetic progression without 
blast count increase. The progressions in the eltrombopag 
group occurred in one patient with refractory anaemia 
with excess blasts-1 and in two patients with unilineage 
dysplasia, with an overall time from diagnosis to 
progression of 5·3 years, 3·6 years, and 14·1 years, 
respectively. Overall, the combined outcome acute myeloid 
leukaemia evolution or disease progression occurred in 
seven (12%) of 59 eltrombopag patients versus five (16%) 
of 31 placebo patients (χ²=0·06, p=0·81). Unrelated death 
occurred in four (7%) of the 59 eltrombopag patients (one 
death from pneumonia, two deaths from heart failure, 
and one death from massive rectal haemorrhage) versus 
two (6%) of the 31 placebo patients (one death from heart 
failure and one death from pneumonia; χ²=0·0, p=1·00). 
Of note, patients with progression or evolution had 
normal karyotype at baseline.
The number needed to treat for a platelet response of at 
least 4 weeks’ duration was 2·3, and the number needed 
to harm for grade 3–4 adverse events was 3·4. The 
number needed to observe acute myeloid leukaemia 
evolution was 28. Thus, the likelihood of being helped or 
harmed, in terms of serious adverse events versus 
efficacy, was 1·5; acute myeloid leukaemia evolution 
versus efficacy was 12·2. Therefore, eltrombopag 
treatment was 1·5–12·2 times more likely to help (in 
terms of platelet response) than to harm.
QOL-E and EORTC QLQ-C30 global health status 
domains at baseline in the whole study sample and 
separately in eltrombopag treated and untreated patients 
are reported in the appendix (pp 11, 12). Although we 
did not find significant changes over time in QOL-E 
items neither within nor between the two study groups, 
QOL-E social, sexual, myelodysplastic syndromes-
specific, treatment outcome index, general, and all 
scores improved with increasing platelet counts 
(appendix pp 13, 14).













Nausea or vomiting 11 3 8 0 0 0
Lower respiratory tract 
infection
0 0 3 0 3 2
Heart failure 0 0 1 0 3 1
Hypertransaminasaemia 2 1 3 1 0 0
Sepsis 0 0 3 0 0 0
Ascites 0 0 2 0 0 0
Bone marrow fibrosis 0 0 2 0 0 0
Myalgia 0 0 2 0 0 0
Solid tumour 0 0 0 0 2 0
Urinary infection 1 1 2 0 0 0
Arrhythmia 0 2 1 1 0 0
Fever 5 4 0 1 1 0
Hyperbilirubinaemia 5 0 1 1 0 0
Skin lesions 6 0 1 1 0 0
Asthenia 6 11 1 0 0 0
Elevated creatinine 0 0 1 0 0 0
Gastric haemorrhage 0 0 1 0 0 0
Microembolism 0 0 1 0 0 0
Pain 11 4 1 0 1 0
Pancreatitis 0 0 1 0 0 0
Proctorrhagy 0 0 1 0 0 0
Pruritus 0 0 1 0 0 0
Rectal bleeding 0 0 0 0 2 0
Renal failure 0 0 1 0 0 0
Respiratory failure 2 1 1 0 0 0
Syncope 0 0 1 0 0 0
Gastric pain 0 0 0 1 0 0
Paraesthesia 2 1 0 0 0 0
Bronchopneumopathy 2 0 0 0 0 0
Herpes virus infection 2 0 0 0 0 0
Diarrhoea 1 1 0 0 0 0
Arthrosis 1 0 0 0 0 0
Bronze-coloured skin 1 0 0 0 0 0
Constipation 1 0 0 0 0 0
Cough 1 0 0 0 0 0
Cramps 1 0 0 0 0 0
Fainting 1 0 0 0 0 0
Headache 1 0 0 0 0 0
Scleral subicterus 1 0 0 0 0 0
Succulent lower limbs 1 0 0 0 0 0
Sweats 1 0 0 0 0 0
Vertigo 0 2 0 0 0 0
Drowsiness 0 1 0 0 0 0
Epithelioma 0 1 0 0 0 0
Gastric burning 0 1 0 0 0 0
Iron overload 0 1 0 0 0 0
All values represent number of events.
Table 2: All non-haematological adverse events
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Discussion
Eltrombopag is effective to increase platelet counts and is 
well tolerated in patients with lower-risk myelodysplastic 
syndromes and severe thrombocytopenia. Thus, both the 
efficacy and safety primary endpoints of this randomised 
trial were met in this first phase, thereby enabling 
commencement of the second phase of the trial (long-term 
follow-up). The stringent platelet cutoff and centralised 
morphology review led to the exclusion of patients with 
immune thrombocytopenia and subtle dysplasia. We 
observed clinically significant responses in nearly half of 
the eltrombopag recipients at a median of 2 weeks, and the 
50 mg dose required to obtain a response was similar to 
that previously reported for patients with severe aplastic 
anaemia.23,24 The platelet responses predominantly seen at 
the low dose of 50 mg might indicate that eltrombopag 
modulates aberrant immune pathways, and thereby acts as 
both a thrombomimetic and an immunomodulatory drug. 
We cannot exclude that some cases had concomitant 
immune thrombocytopenic purpura or idiopathic 
thrombocytopenic purpura, as suggested by spontaneous 
responders in the placebo group. Remarkably, we also 
found that the number of patients who had significant 
bleeding events (WHO bleeding score ≥2) across the 
follow-up was critically lower in the eltrombopag group 
than in the placebo group (14% vs 42%, p=0·0025).
In a phase 2, non-randomised clinical trial in severe 
aplastic anaemia,24 trilineage responses were observed. 
In this trial, erythroid and neutrophil responses were 
evaluable in patients with anaemia and neutropenia 
patients, respectively. Since not all patients were 
pancytopenic, trilineage response was not assessable.
When taking into account patient and disease factors, 
the effect of eltrombopag was strongly correlated only 
with haemoglobin concentrations, possibly indicating an 
association with less severe myelodysplastic syndromes. 
In fact, low haemoglobin concentrations conferred a 
worse prognosis in myelodysplastic syndromes and 
identified patients with a higher risk of progression or 
evolution, thus suggesting more advanced disease. Thus, 
the interaction between haemoglobin and platelet 
response to eltrombopag needs further investigation. In 
any case, our finding underlines the potential benefits of 
eltrombopag in patients with low-risk myelodysplastic 
syndromes not requiring red blood cell transfusions. 
Increasing platelet counts were accompanied by 
improvements in many patient-reported outcomes, as 
captured by the quality-of-life questionnaires.
This trial was possibly limited by its single-blind design; 
however, as it included dose-tailoring and intense safety 
assessments, a double-blind design might not have been 
optimum in an investigator-initiated setting. A key 
concern was the risk of progression to higher-risk 
myelodysplastic syndromes or acute myeloid leukaemia, 
as observed in the randomised trial of romiplostim in a 
similar cohort of patients with low-risk myelodysplastic 
syndromes, in which a more frequent increase in 
peripheral blast count was observed in the active 
treatment versus the placebo group.25 Overall, phase 2 
studies of romiplostim26 as concomitant therapy with 
either hypomethylating (azacitidine, decitabine) 
or immunomo dulatory drugs (lenalidomide) show 
romiplostim as having a similar efficacy profile to 
eltrombopag but with major safety concerns because of 
the systematic rise in blast counts and the potential for 
progression to acute myeloid leukaemia in all studies.26 
Furthermore, in the clinical trial in severe aplastic 
anaemia,24 new cytogenetic abnormalities emerged in 
eight [19%] of 43 patients (with chromosome 7 aberrations 
in five of the eight cases) during eltrombopag treatment; 
the majority occurring in non-responders.24 Of note, 
in-vitro preclinical studies in leukaemia and lymphoma 
cell lines indicate that eltrombopag does not stimulate 
leukaemic cell growth, but inhibits the proliferation of 
many acute myeloid leukaemia cell lines and primary cell 
cultures.27–31 We observed that leukaemic evolution 
occurred more frequently in patients with refractory 
anaemia with excess blasts-1, with no evidence of an 
increased risk in eltrombopag recipients (confirmed by 
blinded, centralised morphological review); the time from 
diagnosis to myelodysplastic syndrome progression or 
acute myeloid leukaemia evolution was sufficient to 
explain the events. Although not investigated in this trial, 
discontinuation of eltrombopag could be contemplated in 
complete responders to shorten the duration of exposure. 
This approach is already established in idiopathic 
thrombocytopenic purpura and alopecia areata.
Efficacy and safety of eltrombopag in high-risk patients 
with myelodysplastic syndromes and in those with 
chronic myelomonocytic leukaemia were recently investi-
gated.32 The authors found that efficacy was more 
prevalent in patients with myelodysplastic syndromes 
than in patients with chronic myelomonocytic leukaemia 
(23% vs 14%), whereas adverse events were more frequent 
in patients with chronic myelomonocytic leukaemia 
(leucocytosis: 71% vs 3%; peripheral myeloblasts: 57% vs 
42%).32 In this study,32 no difference in grade 3 fibrosis 
was observed between the two groups (chronic 
myelomonocytic leukaemia, 14% vs myelodysplastic 
syndromes, 12%). However, given the low number of 
patients with chronic myelomonocytic leukaemia 
enrolled in this study,32 further investigation is needed to 
definitively assess the efficacy and safety of eltrombopag 
in this patient category.
The study protocol contemplates that a p value of 
0·001 or less between the two study groups for both 
primary endpoints (increase in platelet count and 
grade 3 to 4 non-haematological adverse events) 
constitutes a stopping rule for early study termination. 
Although we found a p value for platelet response of less 
than 0·001 between the two study groups, this was not 
found when comparing the proportion of patients with 
grade 3 to 4 non-haematological adverse events (between 
groups comparison, p=0·005). Therefore, the stopping 
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rule was not reached for both primary endpoints, and, 
for this reason, the enrolment will continue to achieve 
the full accrual.
Overall, the findings reported in this study show that 
in patients with lower-risk myelodysplastic syndromes 
and thrombocytopenia, eltrombopag is effective in 
raising platelet counts and well tolerated. The increase 
in platelet count per se is associated with quality-of-life 
improvements. The ongoing phase 2 of the trial is 
designed to assess the long-term duration of response, 
safety, and tolerability of eltrombopag (appendix p 2).
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